Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mobile Stroke Units Deliver Best Emergency Care

By HospiMedica International staff writers
Posted on 22 Sep 2021
A new study shows that mobile stroke units (MSUs) equipped with a computed tomographic (CT) scanner enable faster treatment with tissue plasminogen activator (t-PA) of stroke patients than standard management by emergency medical services (EMS). More...


Researchers at the University of Texas Health Science Center (UTH; Houston, USA), Memorial Hermann Health System (MHHS; Houston, TX, USA), and other institutions conducted an observational, prospective, multicenter, alternating-week trial to assess outcomes of care management within 4.5 hours of onset of acute stroke symptoms in 1,047 patients, in order to evaluate t-PA administration by MSUs (617 patients), as compared to standard management by EMS (430) teams.

The results showed median time from onset of stroke to t-PA administration was 72 minutes in the MSU group and 108 minutes in the EMS group. Of patients eligible for t-PA, 97.1% in the MSU group received it, as compared with 79.5% in the EMS group. Mean score on the utility-weighted modified Rankin scale (at discharge) was 0.57 in the MSU group, and 0.51 in the EMS group, with secondary clinical outcomes generally favoring MSUs. Ninety day mortality was 8.9% in the MSU group and 11.9% in the EMS group. The study was published on September 8, 2021, in the New England Journal of Medicine (NEJM).

“A potential way to reduce the time from stroke onset to treatment is with mobile stroke units ... which are ambulances equipped with a CT scanner, point-of-care laboratory testing, and personnel trained to diagnose and treat patients with stroke in the ambulance, including administration of tPA and triage for endovascular thrombectomy,” concluded lead author James Grotta, MD, of MHHS, and colleagues. “Mobile stroke units have the potential to increase the frequency and speed of the delivery of tPA treatment.”

tPA is a serine protease found on endothelial cells. Its enzymatic role is to catalyze the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. It is thus contraindicated in hemorrhagic stroke and head trauma. When manufactured using recombinant biotechnology methods, it is referred to as recombinant tissue plasminogen activator (rtPA), used to treat embolic or thrombotic stroke.

Related Links:

University of Texas Health Science Center
Memorial Hermann Health System


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.